We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+10.53%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$6.39B
AUM Growth
+$1.46B
Cap. Flow
+$813M
Cap. Flow %
12.72%
Top 10 Hldgs %
30%
Holding
130
New
34
Increased
32
Reduced
37
Closed
15

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$114M
2
CNC icon
Centene
CNC
+$75.1M
3
ESPR
Esperion Therapeutics
ESPR
+$67.2M
4
SPOT icon
Spotify
SPOT
+$55.4M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$51.4M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$198M
2
MSFT icon
Microsoft
MSFT
+$102M
3
BAX icon
Baxter International
BAX
+$84.8M
4
MOH icon
Molina Healthcare
MOH
+$65.2M
5
UNH icon
UnitedHealth
UNH
+$50.1M

Sector Composition

Rank Sector Weight
1 Healthcare 48.69%
2 Technology 9.35%
3 Communication Services 7.21%
4 Consumer Discretionary 2.57%
5 Financials 2.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZS icon
101
Zscaler
ZS
$24.8B
$1.67M 0.03%
46,814
-1,912
-4% -$58.3K
BOX icon
102
Box
BOX
$4.49B
$1.26M 0.02%
50,359
-1,978,380
-98% -$49M
DOCU
103
DocuSign
DOCU
$11.1B
$1.02M 0.02%
+19,199
New +$969K
MSFT icon
104
Microsoft
MSFT
$2.94T
$901K 0.01%
9,138
-1,047,741
-99% -$102M
NOW icon
105
ServiceNow
NOW
$120B
$840K 0.01%
24,340
+505
+2% +$17.5K
BLUE
106
DELISTED
bluebird bio
BLUE
– –
-9,908
Closed -$21.9M
BMY icon
107
CALL
Bristol-Myers Squibb
BMY
$130B
– –
-1,457,500
Closed -$92.2M
BMY icon
108
Bristol-Myers Squibb
BMY
$130B
– –
-3,123,145
Closed -$198M
DXCM icon
109
DexCom
DXCM
$29.2B
– –
-2,056,656
Closed -$38.1M
INGN icon
110
Inogen
INGN
$176M
– –
-1,657
Closed -$204K
OPTN
111
DELISTED
OptiNose
OPTN
– –
-22,286
Closed -$6.69M
RGNX icon
112
Regenxbio
RGNX
$618M
– –
-793,951
Closed -$23.7M
TREE icon
113
LendingTree
TREE
$563M
– –
-51,208
Closed -$16.8M
TSLA icon
114
Tesla
TSLA
$1.2T
– –
-1,088,055
Closed -$19.3M
XNTK icon
115
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.97B
– –
-1,178,800
Closed -$103M
NXGN
116
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
– –
-443,210
Closed -$6.05M
SYNH
117
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
– –
-540,984
Closed -$19.2M
JNCE
118
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-1,923,651
Closed -$43M
GBT
119
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-66,967
Closed -$3.23M
PTLA
120
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-533,300
Closed -$17.4M
1 2 3 4
5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return

PFM Health Sciences's Q2 2018 Portfolio in Review

As of Q2 2018, PFM Health Sciences held 130 positions worth $6.39B, up 30% from $4.92B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

PFM Health Sciences deployed $813M of net new capital in Q2 2018, opening 34 new positions and adding to 32 existing holdings. Its largest new stake was Clovis Oncology, Inc.: 2,337,225 shares worth $106M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 60% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Microsoft, an estimated $102M trimmed.

  • PFM Health Sciences's largest Q2 2018 buy was Clovis Oncology, Inc.: 2,337,225 shares worth $106M.
  • PFM Health Sciences added most to Esperion Therapeutics in Q2 2018, an estimated $67.2M increase.
  • PFM Health Sciences's biggest Q2 2018 reduction was Microsoft, cutting an estimated $102M.
  • PFM Health Sciences fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $198M.
  • PFM Health Sciences's ten largest holdings make up 30% of its $6.39B portfolio in Q2 2018.
  • PFM Health Sciences opened 34 new positions and closed 15 in Q2 2018.
  • PFM Health Sciences's portfolio value rose 30% quarter-over-quarter to $6.39B.

Based on PFM Health Sciences's 13F filing for Q2 2018, filed 14 Aug 2018.